At the end of the treatment period, the total tumor burden present in Slc28a1−/− mice was approximately double that in Slc28a1+/+ mice, as indicated by an increase in the average total bioluminescent flux on day 25 (Figs. 6B and 6C). Here, SLC28A1 is linked to neoplasm.